Immuneering Reports Data in Two Preclinical Abstracts at the ASCO 2022 Annual Meeting Highlighting Pan-KRAS/NRAS Activity of IMM-1-104

Author's Avatar
May 26, 2022

IMM-1-104 strongly inhibits tumor growth in an animal model of KRAS-G12V mutant pancreatic cancer